Trinity Biotech has been granted approval to market its AutoDimer diagnostic which tests for the presence of blood clots in the US.
The test, which has been marketed outside the US since the start of 2000, formed part of the product portfolio purchased in the Biopool acquisition announced in November 2001.
Trinity Biotech develops, manufactures and markets over 200 diagnostic products for the point-of-care, self-testing and clinical laboratory segments of the diagnostic market.
Mr Ronan O'Caoimh, Trinity Biotech's chief executive said Autodiner is designed to satisfy the needs of the broadest range of laboratories. He said laboratories of all sizes can take advantage of both the cost effectiveness and the diagnostic
Biopool, which was acquired by Trinity Biotech in December of 2001, makes test kits to assess and diagnose disorders associated with blood disorders.